Glaxo Smith Kline results, Q4 2025
Net profit, assets, equity and cash flow for Q4 2025, against the same period a year earlier, from the published financial statements.
Net profit183 millionEGP · +168.5% vs the same period a year earlier
Total assets4.5 billionEGP · +23.2% vs the same period a year earlier
Shareholders' equity2.22 billionEGP · +11.1% vs the same period a year earlier
Operating cash flow111 millionEGP · +159.2% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Q4 2025 was about 183 million EGP, up +168.5% from 68.15 million EGP in Q4 2024.
- Total assets at the end of Q4 2025 were about 4.5 billion EGP, and shareholders' equity about 2.22 billion EGP.
- Operating cash flow for Q4 2025 was positive at 111 million EGP.
Key lines against the same period a year earlier
This periodQ4 2024Change
Net profit183 million68.15 million+168.5%
Gross profit289 million282 million+2.2%
Total assets4.5 billion3.65 billion+23.2%
Total liabilities—1.66 billion—
Shareholders' equity2.22 billion2 billion+11.1%
Total liabilities and equity4.5 billion3.65 billion+23.2%
Operating cash flow111 million-188 million+159.2%
Investing cash flow-89.13 million54.37 million−263.9%
Financing cash flow115 million-3.45 million+3434.7%
Net change in cash137 million-137 million+200.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy